% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Spohn:274453,
      author       = {S. K. B. Spohn$^*$ and C. Zamboglou$^*$ and A. L.
                      Grosu$^*$},
      title        = {{M}odern radiotherapy of primary prostate cancer.[{M}oderne
                      {S}trahlentherapie des primären {P}rostatakarzinoms.]},
      journal      = {Best Practice Onkologie},
      volume       = {18},
      number       = {4},
      issn         = {0946-4565},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2023-00598},
      pages        = {130–137},
      year         = {2023},
      note         = {18, pages 130–137 (2023)},
      abstract     = {Prostate cancer (PCa) is the most frequent malignant
                      disease in men. While patients with a low risk profile can
                      be actively monitored (watchful waiting), radiotherapy and
                      surgery are equivalent therapeutic options for patients with
                      an intermediate or high risk profile. Modern radiotherapy
                      allows a reduction in treatment time to 2–4 weeks via
                      hypofractionation or stereotactic body radiotherapy (SBRT),
                      is associated with a low rate of adverse events, and enables
                      personalized treatment adapted to the individual anatomy and
                      tumor geometry. Information from multiparametric MRI (mpMRI)
                      and positron-emission tomography with tracers targeting the
                      prostate-specific membrane antigen (PSMA-PET) can be
                      considered during treatment planning. Using focal dose
                      escalation, the radiation dose to the tumor in the prostate
                      can be increased, without further exposure of proximal
                      organs. The HypoFocal-SBRT study, a multicentric phase III
                      trial funded by the National Decade Against Cancer, is
                      investigating the possible benefit of SBRT in five fractions
                      with dose escalation to the intraprostatic tumor lesions
                      defined by mpMRT and PSMA-PET. The aim of this study is to
                      further improve the recurrence-free survival of patients
                      with localized PCa of intermediate and high risk profile
                      while simultaneously reducing the treatment time.},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1007/s11654-023-00473-0},
      url          = {https://inrepo02.dkfz.de/record/274453},
}